September 22, 2014. The Food and Drug Administration (FDA) is “proposing changes to the definition of class III to provide greater clarity regarding which devices fall within this class, and to improve transparency and predictability in device classification and reclassification decisions.” We commend the FDA for seeking clarity but we have grave concerns about the ways that the proposed rule weakens current definitions of class III devices.
Read More »On Medical Treatments & Products
Comments on Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communication Devices
August 25, 2014. With this draft guidance, the FDA is notifying manufacturers and others that it “does not intend to enforce compliance with regulatory controls that apply to” medical device data systems (MDDS), medical image storage devices, and medical image communications devices. The FDA has stated it is using its enforcement discretion on these devices because of “the low risk they pose to patients and the importance they play in advancing digital health.” We strongly disagree.
Read More »NCHR Testimony at FDA Advisory Panel on Liraglutide
September 11, 2014. NCHR states that, after careful review of the data, we are skeptical about whether Liraglutide meets the standards of safety and efficacy that patients and consumers deserve.
Read More »NCHR Testimony at FDA on Nebivolol/Valsartan for Treating Hypertension
September 9, 2014. We share the FDA’s reservations about the clinical relevance of the small reductions in blood pressure. We question whether approving this combination drug will make a difference in patients’ health.
Read More »NCHR Testimony at FDA Advisory Panel on TissuGlu
August 1, 2014. The product was NOT studied on cancer patients and definitely should not be approved for them. In fact, the label should specify that it has not been studied on cancer patients.
Read More »